Analysis highlights the obligations of drug companies and governments to ensure equitable access to new drugs, suggesting improved healthcare access for patients' rights.
The obligations and responsibilities of governments and drug companies to increase access to costly new drugs should be grounded in international human rights, write Trudo Lemmens and colleagues
No takes yet. Share an insight, caveat, or question.
Lemmens et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: